- Home
- NPCE vs OCGN Comparison
NPCE vs OCGN Comparison
Compare NPCE & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- OCGN
- Stock Information
- Founded
- NPCE 1997
- OCGN 2013
- Country
- NPCE United States
- OCGN United States
- Employees
- NPCE N/A
- OCGN N/A
- Industry
- NPCE Medical Specialities
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPCE Health Care
- OCGN Health Care
- Exchange
- NPCE Nasdaq
- OCGN Nasdaq
- Market Cap
- NPCE 342.7M
- OCGN 321.7M
- IPO Year
- NPCE 2021
- OCGN N/A
- Fundamental
- Price
- NPCE $10.82
- OCGN $1.63
- Analyst Decision
- NPCE Strong Buy
- OCGN Strong Buy
- Analyst Count
- NPCE 6
- OCGN 3
- Target Price
- NPCE $16.67
- OCGN $6.00
- AVG Volume (30 Days)
- NPCE 149.8K
- OCGN 8.5M
- Earning Date
- NPCE 11-11-2025
- OCGN 11-07-2025
- Dividend Yield
- NPCE N/A
- OCGN N/A
- EPS Growth
- NPCE N/A
- OCGN N/A
- EPS
- NPCE N/A
- OCGN N/A
- Revenue
- NPCE $88,570,000.00
- OCGN $4,754,000.00
- Revenue This Year
- NPCE $22.13
- OCGN N/A
- Revenue Next Year
- NPCE $6.07
- OCGN N/A
- P/E Ratio
- NPCE N/A
- OCGN N/A
- Revenue Growth
- NPCE 23.32
- OCGN N/A
- 52 Week Low
- NPCE $5.45
- OCGN $0.52
- 52 Week High
- NPCE $18.98
- OCGN $1.90
- Technical
- Relative Strength Index (RSI)
- NPCE 57.95
- OCGN 56.42
- Support Level
- NPCE $10.25
- OCGN $1.31
- Resistance Level
- NPCE $11.25
- OCGN $1.88
- Average True Range (ATR)
- NPCE 0.50
- OCGN 0.15
- MACD
- NPCE -0.02
- OCGN -0.02
- Stochastic Oscillator
- NPCE 65.44
- OCGN 43.88
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").